Therapeutic HBV Vaccine Using PreS1/PreS2 Regions
Summary
The European Patent Office published patent application EP3710049A1 for a therapeutic Hepatitis B Virus (HBV) vaccine developed by the University of Washington. The patent covers the use of PreS1/PreS2 regions of the HBV envelope protein as vaccine antigens. This publication affects entities engaged in HBV vaccine research or commercialization within EPO-designated states.
What changed
EPO published patent application EP3710049A1, filed by University of Washington inventors Edward A. Clark, Che-Leung Law, Deborah Fuller, and Michael Gale, covering a therapeutic HBV vaccine using PreS1/PreS2 and/or S-HBsAg regions of the HBV envelope protein. The application is classified under IPC codes A61K 39/12, A61K 39/29, A61K 39/00, and C07K 16/28, with designated states covering all major European jurisdictions including DE, FR, GB, IT, ES, NL, and 25 other EPO member states.
Pharmaceutical and biotechnology companies engaged in HBV vaccine development should review freedom-to-operate implications and consider patent landscape analysis for their existing or planned HBV therapeutic programs. Research institutions and vaccine developers should assess whether this patent coverage affects their development activities in the designated territories.
What to do next
- Conduct freedom-to-operate analysis for HBV vaccine programs in EPO-designated territories
- Review patent claims for potential licensing or coexistence strategies
- Monitor the patent prosecution for scope limitations during examination
Archived snapshot
Apr 1, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A THERAPEUTIC VACCINE FOR HEPATITIS B VIRUS (HBV) USING THE HBV PRES1 AND/OR PRES2, AND/OR S-HBSAG REGIONS OF THE HBV ENVELOPE PROTEIN
Publication EP3710049A1 Kind: A1 Mar 25, 2026
Applicants
University of Washington
Inventors
CLARK, Edward, A., LAW, Che-Leung, FULLER, Deborah, GALE, Michael
IPC Classifications
A61K 39/12 20060101AFI20211126BHEP A61K 39/29 20060101ALI20211126BHEP A61K 39/00 20060101ALI20211126BHEP C07K 16/28 20060101ALI20211126BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.